Jubilee Brown to Endometrial Neoplasms
This is a "connection" page, showing publications Jubilee Brown has written about Endometrial Neoplasms.
Connection Strength
1.592
-
André T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, Ellard S, de Braud F, Arkenau HT, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano YA, Samouëlian V, Miller R, Boni V, Torres AA, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 Nov 01; 6(11):e2341165.
Score: 0.199
-
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C, Dong Y, Veneris J, Pothuri B. A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncol. 2023 Aug; 19(25):1709-1714.
Score: 0.194
-
Lees BF, Johnson S, Donahue E, Bose R, Brown J, Crane E, Puechl A, Tait D, Naumann RW. Improved Rates of Same-day Discharge in Patients Undergoing Surgery for Endometrial Cancer Following the COVID-19 Pandemic. J Minim Invasive Gynecol. 2022 Nov; 29(11):1248-1252.
Score: 0.182
-
Wilhite AM, Baca Y, Xiu J, Paladugu R, ElNaggar AC, Brown J, Winer IS, Morris R, Erickson BK, Olawaiye AB, Powell M, Korn WM, Rocconi RP, Khabele D, Jones NL. Molecular profiles of endometrial cancer tumors among Black patients. Gynecol Oncol. 2022 Jul; 166(1):108-116.
Score: 0.179
-
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022 Jan; 10(1).
Score: 0.175
-
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021 Oct 01; 17(29):3781-3785.
Score: 0.171
-
Crane EK, Brown J, Lehman A, Tait DL, Naumann RW. Perioperative Recovery and Narcotic Use in Laparoscopic versus Robotic Surgery for Endometrial Cancer. J Minim Invasive Gynecol. 2021 Nov; 28(11):1898-1902.
Score: 0.167
-
Tait DL, Lehman A, Brown J, Crane EK, Kemp EV, Taylor VD, Naumann RW. Comparison of Perioperative Outcomes between Minimally Invasive Sentinel Node Biopsy and Full Lymphadenectomy for Endometrial Cancer. J Minim Invasive Gynecol. 2021 Aug; 28(8):1514-1518.
Score: 0.163
-
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):1766-1772.
Score: 0.161